Nexavar treatment consistently showed benefit in hepatocellular carcinoma regardless of prognostic factors, according to results of a recently published study.
“Although analyses of potential predictive factors for sorafenib benefit have been attempted with data from single-arm, observational studies, the lack of a placebo arm in these trials has prevented proper differentiation between prognostic and predictive markers,” Jordi Bruix, MD, from the BLCL Hospital Clinic Barcelona, Spain, and colleagues wrote. “Our analysis showed a consistent OS benefit with sorafenib treatment compared with placebo irrespective of patient baseline characteristics, subgroup or prognostic factors for survival.”
Continue reading.....
Recommended Reading @ Healio
Acute renal failure predicts mortality in cirrhotic patients with...
SVR leads to survival benefit among HCV patients
Postmenopausal estrogen use reduces risk for HCC
Free registration may be required
No comments:
Post a Comment